AI assistant
Sending…
UroGen Pharma Ltd. — Director's Dealing 2026
Feb 27, 2026
32312_dirs_2026-02-27_85d28aff-d71b-455e-8d62-4512fa75c457.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2026-02-26
Reporting Person: Robinson James A. Jr. (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-02-26 | ordinary shares | M | 2000 | — | Acquired | 4000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-02-26 | Restricted Stock Unit | $ | M | 2000 | Disposed | Ordinary Shares (2000) | Direct |
Footnotes
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer
More from UroGen Pharma Ltd.
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 6
Proxy Solicitation & Information Statement
2026
Apr 30
Annual Report
2026
Mar 2
Regulatory Filings
2026
Mar 2
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 19
Director's Dealing
2026
Feb 11
Director's Dealing
2026
Feb 4
Director's Dealing
2026
Feb 3